Palmar-plantar erythrodysesthesia syndrome resulting from toceranib phosphate in a dog with apocrine gland anal sac adenocarcinoma: a case report

An 11-year-old neutered male Miniature Poodle with a stage 3 apocrine gland adenocarcinoma was started on chemotherapy with toceranib phosphate after surgery. Beginning on day 10 of toceranib, the dog's foot pads became erythematous and hyperkeratinized. The dog complained of pain, inability to...

Full description

Saved in:
Bibliographic Details
Published inJournal of veterinary science (Suwŏn-si, Korea) Vol. 24; no. 6; pp. 76.1 - 76.6
Main Authors Eunjoo Kim, Sung-Soo Kim, Min-Ok Ryu
Format Journal Article
LanguageKorean
Published 2023
Subjects
canine diseases
Case reports
hand-foot syndrome
tyrosine protein kinase inhibitor
Online AccessGet full text

Cover

More Information
Summary:An 11-year-old neutered male Miniature Poodle with a stage 3 apocrine gland adenocarcinoma was started on chemotherapy with toceranib phosphate after surgery. Beginning on day 10 of toceranib, the dog's foot pads became erythematous and hyperkeratinized. The dog complained of pain, inability to walk, depression, and loss of appetite. The symptoms resolved when toceranib was discontinued and reappeared when toceranib was resumed. Grade 3 palmar-plantar erythrodysesthesia was identified as an adverse event of toceranib based on the VCOG-CTCAE and Naranjo scale. Although very rare in veterinary medicine, clinicians should consider that palmar-plantar erythrodysesthesia can occur after toceranib administration.
Bibliography:KISTI1.1003/JNL.JAKO202335243254708
ISSN:1229-845X
1976-555X